Spinal Cord Cellular Therapeutics Delivery: Device Design Considerations

  • Khalid Medani
  • Jonathan Riley
  • Jason Lamanna
  • Nicholas BoulisEmail author
Part of the Stem Cell Biology and Regenerative Medicine book series (STEMCELL)


Cell-based therapeutics are being increasingly trialed in both preclinical and clinical contexts for the treatment of multiple forms of intrinsic spinal cord pathology with either neuroprotective or neurorestorative intent. This therapeutic paradigm is being explored for the treatment of neurodegenerative (e.g., amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA)) and traumatic (e.g., spinal cord injury) indications. Cell-based therapies may also be considered for alternative indications such as multiple sclerosis and intramedullary neoplasms. Multiple delivery approaches may be considered to deliver a cellular therapy to the spinal cord. Preclinical and clinical studies have explored intravascular, intrathecal (e.g., subarachnoid), and intraparenchymal delivery approaches. In this chapter, we briefly describe the different cell delivery approaches and will primarily focus on the technical considerations encountered in the development of an intraparenchymal microinjection approach. An emphasis will be placed on areas of interest that continue to be investigated. The chapter concludes with an introduction of technologies that may augment next generation cell delivery approaches.


Cell therapy Intraspinal microinjection Spinal cord injection Stem cell 


  1. 1.
    Riley J et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery. 2012;71(2):405–16. discussion 416.CrossRefPubMedGoogle Scholar
  2. 2.
    Glass JD et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells. 2012;30(6):1144–51.CrossRefPubMedGoogle Scholar
  3. 3.
    Knoller N et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine. 2005;3(3):173–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Jones LA et al. A phase 2 autologous cellular therapy trial in patients with acute, complete spinal cord injury: pragmatics, recruitment, and demographics. Spinal Cord. 2010;48(11):798–807.CrossRefPubMedGoogle Scholar
  5. 5.
    Lammertse DP et al. Autologous incubated macrophage therapy in acute, complete spinal cord injury: results of the phase 2 randomized controlled multicenter trial. Spinal Cord. 2012;50(9):661–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Blanquer M et al. Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study. Stem Cells. 2012;30(6):1277–85.CrossRefPubMedGoogle Scholar
  7. 7.
    Mazzini L et al. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy. 2012;14(1):56–60.CrossRefPubMedGoogle Scholar
  8. 8.
    Mazzini L et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp Neurol. 2010;223(1):229–37.CrossRefPubMedGoogle Scholar
  9. 9.
    Mazzini L et al. Mesenchymal stem cells for ALS patients. Amyotroph Lateral Scler. 2009;10(2):123–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Mazzini L et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(3):158–61.CrossRefPubMedGoogle Scholar
  11. 11.
    Chapman AR, Scala CC. Evaluating the first-in-human clinical trial of a human embryonic stem cell-based therapy. Kennedy Inst Ethics J. 2012;22(3):243–61.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhou XH et al. Transplantation of autologous activated Schwann cells in the treatment of spinal cord injury: six cases, more than five years of follow-up. Cell Transplant. 2012;21 Suppl 1:S39–47.CrossRefPubMedGoogle Scholar
  13. 13.
    Huang H et al. Long-term outcome of olfactory ensheathing cell therapy for patients with complete chronic spinal cord injury. Cell Transplant. 2012;21 Suppl 1:S23–31.CrossRefPubMedGoogle Scholar
  14. 14.
    Wu J et al. Clinical observation of fetal olfactory ensheathing glia transplantation (OEGT) in patients with complete chronic spinal cord injury. Cell Transplant. 2012;21 Suppl 1:S33–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Attar A et al. An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells. Cytotherapy. 2011;13(1):54–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Lima C et al. Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury. Neurorehabil Neural Repair. 2010;24(1):10–22.CrossRefPubMedGoogle Scholar
  17. 17.
    Lima C et al. Olfactory mucosa autografts in human spinal cord injury: a pilot clinical study. J Spinal Cord Med. 2006;29(3):191–203. discussion 204–6.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Deda H et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy. 2009;11(1):18–25.CrossRefPubMedGoogle Scholar
  19. 19.
    Feron F et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain. 2005;128(Pt 12):2951–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Mackay-Sim A et al. Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial. Brain. 2008;131(Pt 9):2376–86.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Saberi H et al. Treatment of chronic thoracic spinal cord injury patients with autologous Schwann cell transplantation: an interim report on safety considerations and possible outcomes. Neurosci Lett. 2008;443(1):46–50.CrossRefPubMedGoogle Scholar
  22. 22.
    Saberi H et al. Safety of intramedullary Schwann cell transplantation for postrehabilitation spinal cord injuries: 2-year follow-up of 33 cases. J Neurosurg Spine. 2011;15(5):515–25.CrossRefPubMedGoogle Scholar
  23. 23.
    Yoon SH et al. Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: phase I/II clinical trial. Stem Cells. 2007;25(8):2066–73.CrossRefPubMedGoogle Scholar
  24. 24.
    Chen L et al. Short-term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2007;21(9):961–6.PubMedGoogle Scholar
  25. 25.
    Liu J et al. Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells. Cytotherapy. 2013;15(2):185–91.CrossRefPubMedGoogle Scholar
  26. 26.
    Sharma A et al. Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplant. 2012;21 Suppl 1:S79–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Frolov AA, Bryukhovetskiy AS. Effects of hematopoietic autologous stem cell transplantation to the chronically injured human spinal cord evaluated by motor and somatosensory evoked potentials methods. Cell Transplant. 2012;21 Suppl 1:S49–55.CrossRefPubMedGoogle Scholar
  28. 28.
    Karamouzian S et al. Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Clin Neurol Neurosurg. 2012;114(7):935–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Saito F et al. Administration of cultured autologous bone marrow stromal cells into cerebrospinal fluid in spinal injury patients: a pilot study. Restor Neurol Neurosci. 2012;30(2):127–36.PubMedGoogle Scholar
  30. 30.
    Saito F et al. Spinal cord injury treatment with intrathecal autologous bone marrow stromal cell transplantation: the first clinical trial case report. J Trauma. 2008;64(1):53–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Karussis D et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67(10):1187–94.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Kumar AA et al. Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: a phase I/II clinical safety and primary efficacy data. Exp Clin Transplant. 2009;7(4):241–8.PubMedGoogle Scholar
  33. 33.
    Pal R et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot clinical study. Cytotherapy. 2009;11(7):897–911.CrossRefPubMedGoogle Scholar
  34. 34.
    Mehta T et al. Subarachnoid placement of stem cells in neurological disorders. Transplant Proc. 2008;40(4):1145–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Ra JC et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011;20(8):1297–308.CrossRefPubMedGoogle Scholar
  36. 36.
    Xu J et al. Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. Ann Hematol. 2011;90(3):343–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Cristante AF et al. Stem cells in the treatment of chronic spinal cord injury: evaluation of somatosensitive evoked potentials in 39 patients. Spinal Cord. 2009;47(10):733–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Moviglia GA et al. Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy. 2006;8(3):202–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Habisch HJ et al. Intrathecal application of neuroectodermally converted stem cells into a mouse model of ALS: limited intraparenchymal migration and survival narrows therapeutic effects. J Neural Transm. 2007;114(11):1395–406.CrossRefPubMedGoogle Scholar
  40. 40.
    Mothe AJ et al. Intrathecal transplantation of stem cells by lumbar puncture for thoracic spinal cord injury in the rat. Spinal Cord. 2011;49(9):967–73.CrossRefPubMedGoogle Scholar
  41. 41.
    Neuhuber B et al. Stem cell delivery by lumbar puncture as a therapeutic alternative to direct injection into injured spinal cord. J Neurosurg Spine. 2008;9(4):390–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Takahashi Y et al. Comparative study of methods for administering neural stem/progenitor cells to treat spinal cord injury in mice. Cell Transplant. 2011;20(5):727–39.CrossRefPubMedGoogle Scholar
  43. 43.
    Garcia S et al. Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Exp Cell Res. 2010;316(9):1648–50.CrossRefPubMedGoogle Scholar
  44. 44.
    Torsvik A et al. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res. 2010;70(15):6393–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Furlani D et al. Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res. 2009;77(3):370–6.CrossRefPubMedGoogle Scholar
  46. 46.
    Riley J et al. Intraspinal stem cell transplantation in ALS: a phase I safety trial, technical note & lumbar safety outcomes. Neurosurgery. 2012;71(2):405–16.CrossRefPubMedGoogle Scholar
  47. 47.
    Riley J et al. Intraspinal stem cell transplantation in ALS: a phase I trial, cervical microinjection and final surgical safety outcomes. Neurosurgery. 2013;74(1):77–87.CrossRefGoogle Scholar
  48. 48.
    Safety Study of GRNOPC1 in Spinal Cord Injury. [cited 9 Jan 2011]. Available from:
  49. 49.
    Huang H et al. Safety of fetal olfactory ensheathing cell transplantation in patients with chronic spinal cord injury. A 38-month follow-up with MRI. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2006;20(4):439–43.PubMedGoogle Scholar
  50. 50.
    Huang H et al. Influence of patients’ age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin Med J (Engl). 2003;116(10):1488–91.Google Scholar
  51. 51.
    Dobkin BH, Curt A, Guest J. Cellular transplants in China: observational study from the largest human experiment in chronic spinal cord injury. Neurorehabil Neural Repair. 2006;20(1):5–13.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Blanquer M et al. Bone marrow stem cell transplantation in amyotrophic lateral sclerosis: technical aspects and preliminary results from a clinical trial. Methods Find Exp Clin Pharmacol. 2010;32(Suppl A):31–7.PubMedGoogle Scholar
  53. 53.
    Blanquer M et al. A surgical technique of spinal cord cell transplantation in amyotrophic lateral sclerosis. J Neurosci Methods. 2010;191(2):255–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Casanova F, Carney PR, Sarntinoranont M. Influence of needle insertion speed on backflow for convection-enhanced delivery. J Biomech Eng. 2012;134(4):041006.CrossRefPubMedGoogle Scholar
  55. 55.
    Krauze MT et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg. 2005;103(5):923–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Yin D, Forsayeth J, Bankiewicz KS. Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods. 2010;187(1):46–51.CrossRefPubMedGoogle Scholar
  57. 57.
    Vazquez LC et al. Polymer-coated cannulas for the reduction of backflow during intraparenchymal infusions. J Mater Sci Mater Med. 2012;23(8):2037–46.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Cunningham MG et al. Preclinical evaluation of a novel intracerebral microinjection instrument permitting electrophysiologically guided delivery of therapeutics. Neurosurgery. 2004;54(6):1497–507. discussion 1507.CrossRefPubMedGoogle Scholar
  59. 59.
    Bjarkam CR et al. Safety and function of a new clinical intracerebral microinjection instrument for stem cells and therapeutics examined in the Gottingen minipig. Stereotact Funct Neurosurg. 2010;88(1):56–63.CrossRefPubMedGoogle Scholar
  60. 60.
    Potts MB, Silvestrini MT, Lim DA. Devices for cell transplantation into the central nervous system: design considerations and emerging technologies. Surg Neurol Int. 2013;4 Suppl 1:S22–30.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Skuk D et al. Ischemic central necrosis in pockets of transplanted myoblasts in nonhuman primates: implications for cell-transplantation strategies. Transplantation. 2007;84(10):1307–15.CrossRefPubMedGoogle Scholar
  62. 62.
    Parsa S et al. Effects of surfactant and gentle agitation on inkjet dispensing of living cells. Biofabrication. 2010;2(2):025003.CrossRefPubMedGoogle Scholar
  63. 63.
    Aguado BA et al. Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng Part A. 2012;18(7–8):806–15.CrossRefPubMedGoogle Scholar
  64. 64.
    Lu P et al. Long-distance growth and connectivity of neural stem cells after severe spinal cord injury. Cell. 2012;150(6):1264–73.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Riley J et al. Targeted spinal cord therapeutics delivery: stabilized platform and microelectrode recording guidance validation. Stereotact Funct Neurosurg. 2008;86(2):67–74.CrossRefPubMedGoogle Scholar
  66. 66.
    Kang JH et al. Development of a sodium/iodide symporter (NIS)-transgenic mouse for imaging of cardiomyocyte-specific reporter gene expression. J Nucl Med. 2005;46(3):479–83.PubMedGoogle Scholar
  67. 67.
    MacLaren DC et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther. 1999;6(5):785–91.CrossRefPubMedGoogle Scholar
  68. 68.
    Arena F et al. beta-Gal gene expression MRI reporter in melanoma tumor cells. Design, synthesis, and in vitro and in vivo testing of a Gd(III) containing probe forming a high relaxivity, melanin-like structure upon beta-Gal enzymatic activation. Bioconjug Chem. 2011;22(12):2625–35.CrossRefPubMedGoogle Scholar
  69. 69.
    Bengtsson NE et al. lacZ as a genetic reporter for real-time MRI. Magn Reson Med. 2010;63(3):745–53.CrossRefPubMedGoogle Scholar
  70. 70.
    Yaghoubi SS et al. Noninvasive detection of therapeutic cytolytic T cells with 18F–FHBG PET in a patient with glioma. Nat Clin Pract Oncol. 2008;6(1):53–8.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Zurkiya O, Chan AWS, Hu X. MagA is sufficient for producing magnetic nanoparticles in mammalian cells, making it an MRI reporter. Magn Reson Med. 2008;59(6):1225–31.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Genove G et al. A new transgene reporter for in vivo magnetic resonance imaging. Nat Med. 2005;11(4):450–4.CrossRefPubMedGoogle Scholar
  73. 73.
    Li Z et al. Comparison of reporter gene and iron particle labeling for tracking fate of human embryonic stem cells and differentiated endothelial cells in living subjects. Stem Cells. 2008;26(4):864–73.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Gonzalez-Lara LE et al. The use of cellular magnetic resonance imaging to track the fate of iron-labeled multipotent stromal cells after direct transplantation in a mouse model of spinal cord injury. Mol Imaging Biol. 2011;13(4):702–11.CrossRefPubMedGoogle Scholar
  75. 75.
    Guzman R et al. Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI. Proc Natl Acad Sci. 2007;104(24):10211–6.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Obenaus A et al. Long-term magnetic resonance imaging of stem cells in neonatal ischemic injury. Ann Neurol. 2011;69(2):282–91.CrossRefPubMedGoogle Scholar
  77. 77.
    Zhu J, Zhou L, XingWu F. Tracking neural stem cells in patients with brain trauma. N Engl J Med. 2006;355(22):2376–8.CrossRefPubMedGoogle Scholar
  78. 78.
    Callera F, de Melo CM. Magnetic resonance tracking of magnetically labeled autologous bone marrow CD34+ cells transplanted into the spinal cord via lumbar puncture technique in patients with chronic spinal cord injury: CD34+ cells’ migration into the injured site. Stem Cells Dev. 2007;16(3):461–6.CrossRefPubMedGoogle Scholar
  79. 79.
    Kanpolat Y. Percutaneous destructive pain procedures on the upper spinal cord and brain stem in cancer pain: CT-guided techniques, indications and results. Adv Tech Stand Neurosurg. 2007;32:147–73.CrossRefPubMedGoogle Scholar
  80. 80.
    Kanpolat Y et al. CT-guided percutaneous selective cordotomy. Acta Neurochir (Wien). 1993;123(1–2):92–6.CrossRefGoogle Scholar
  81. 81.
    McGirt MJ et al. MRI-guided frameless stereotactic percutaneous cordotomy. Stereotact Funct Neurosurg. 2002;78(2):53–63.CrossRefPubMedGoogle Scholar
  82. 82.
    Lee JH et al. Percutaneous transplantation of human umbilical cord blood-derived multipotent stem cells in a canine model of spinal cord injury. J Neurosurg Spine. 2009;11(6):749–57.CrossRefPubMedGoogle Scholar
  83. 83.
    Larson PS et al. An optimized system for interventional magnetic resonance imaging-guided stereotactic surgery: preliminary evaluation of targeting accuracy. Neurosurgery. 2012;70(1 Suppl Operative):95–103. discussion 103.PubMedGoogle Scholar
  84. 84.
    Martin AJ et al. Placement of deep brain stimulator electrodes using real-time high-field interventional magnetic resonance imaging. Magn Reson Med. 2005;54(5):1107–14.CrossRefPubMedGoogle Scholar
  85. 85.
    Starr PA et al. Subthalamic nucleus deep brain stimulator placement using high-field interventional magnetic resonance imaging and a skull-mounted aiming device: technique and application accuracy. J Neurosurg. 2010;112(3):479–90.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Khalid Medani
    • 1
  • Jonathan Riley
    • 1
  • Jason Lamanna
    • 1
    • 2
  • Nicholas Boulis
    • 1
    Email author
  1. 1.Department of NeurosurgeryEmory UniversityAtlantaUSA
  2. 2.Department of Biomedical EngineeringGeorgia Institute of Technology, Emory UniversityAtlantaUSA

Personalised recommendations